What Was Approved?
On May 29, 2026, the U.S. Food and Drug Administration approved Cypsedo (cipepofol) for the induction of general anesthesia in adults undergoing surgery.
Cypsedo is given intravenously and is intended for use by trained healthcare professionals in a monitored medical setting.
How Is Cypsedo Given?
Cypsedo is administered by intravenous injection shortly before surgery.
The FDA-approved dose is weight-based and depends on factors such as:
- Age
- Body mass index
- American Society of Anesthesiologists Physical Status classification
If the initial dose does not provide adequate induction, an additional dose may be given according to the prescribing information.
What Are the Main Safety Concerns?
The prescribing information includes several important warnings.
Cypsedo can cause:
- Low blood pressure
- Slow heart rate
- Respiratory depression
- Reduced oxygen levels
Patients should be continuously monitored for cardiovascular and respiratory changes during administration.
Can Allergic Reactions Occur?
Yes.
Serious hypersensitivity reactions, including anaphylaxis, have been reported.
Cypsedo is contraindicated in patients with known hypersensitivity to the drug or its ingredients, and in patients with a history of anaphylaxis to eggs, egg products, soybeans, or soy products.
What Are the Common Side Effects?
Common adverse reactions reported in clinical studies included:
- Hypotension
- Nausea
- Injection-site pain
- Vomiting
- Dizziness
- Hypoxia
- Bradycardia
- Headache
Other adverse effects can also occur.
Is Cypsedo Approved for Children?
No.
The FDA-approved indication is for adults undergoing surgery.
The prescribing information states that Cypsedo is not approved for pediatric patients.
Bottom Line
Cypsedo (cipepofol) is a newly FDA-approved intravenous general anesthetic used to induce anesthesia in adults undergoing surgery.
Because it can affect blood pressure, heart rate, breathing, and oxygen levels, it must be administered in a properly monitored medical setting by qualified healthcare professionals.
Sources
- U.S. Food and Drug Administration (FDA) — Novel Drug Approvals for 2026.
- U.S. Food and Drug Administration (FDA) — Cypsedo (cipepofol) Prescribing Information, revised May 2026.